Altered Tryptophan Metabolism in FIV‐Positive Cats

Abstract

Background:Feline immunodeficiency virus (FIV) is analogous to human immunodeficiency virus, the causative agent of human acquired immunodeficiency syndrome (AIDS). In AIDS patients, a progressive reduction in serum tryptophan concentration occurs because of activation of an inducible tryptophan degradation pathway mediated by elevated Λ‐interferon production.Hypothesis:Cats infected with FIV have increased tryptophan catabolism evidenced by reduced circulating concentrations of tryptophan and increased concentrations of the tryptophan catabolite kynurenine.Animals:Convenience sample of 235 cats submitted for diagnostic FIV serology (115 FIV‐negative and 120 FIV‐positive cats).Methods:Retrospective, cross‐sectional study. Serum was assayed for tryptophan and kynurenine using a high performance liquid chromatography assay with fluorescence and ultraviolet detection, respectively.Results:Tryptophan and kynurenine concentrations were log‐normally distributed. Geometric mean concentrations were: tryptophan: FIV‐positive 30.6 μM (95% CI: 26.8–34.8 μM), FIV‐negative 48.9 μM (95% CI: 43.6–54.9 μM) (P < .001); kynurenine: FIV‐positive 22.7 μM (95% CI: 25.5–10.9 μM), FIV‐negative 9.9 μM (95% CI: 20.3–9.03 μM) (P < .001). The ratio of kynurenine to tryptophan was: FIV‐positive 4.93 (95% CI: 5.62–4.32), FIV‐negative 1.34 (95% CI: 1.53–1.17) (P < .0001).Conclusions and Clinical Importance: Serum tryptophan concentration was significantly lower and serum kynurenine concentration was significantly higher in FIV‐positive cats. The kynurenine: tryptophan ratio was >3‐fold higher in FIV‐positive animals, indicating increased tryptophan catabolism in this group. Dietary or pharmacologic intervention to support serum tryptophan concentrations has been shown to be clinically useful in humans with AIDS and might be applicable to cats with FIV infection.